Patient Registry of Posner-Schlossman Syndrome

Posner-Schlossman syndrome, or glaucomatocyclitic crisis, is a condition characterized by recurrent, acute attacks of mild, nongranulomatous, anterior uveitis accompanied by markedly elevated intraocular pressure. Most of patients are the 20 to 50-year-old young adults, with unilateral eye involvement. PSS was originally deemed benign, but is now recognized as a relatively rare cause of chronic secondary glaucoma,especially in patients with recurrent episodes. This relatively rare disease is likely the result of the infections of a variety of organisms, and the bulk of literature supports the cytomegalovirus (CMV) as the leading cause.

This study is an observational study that does not interfere with the normal clinical diagnosis and treatment process. The investigators in this study focus on observing the clinical symptoms and outcome of PSS, analyzing the factors that affect the prognosis of PSS, studying the association of its pathogenesis with the psychological status and the behavioral types of PSS patients; exploring the relationship between infection (CMV, HSV, Hp) and PSS; and studying the changes of local and systemic cytokine expression and its significance in patients with PSS.

Study Overview

• Status: Recruiting
• Conditions: Posner Schlossman Syndrome

• Study Type: Observational
• Enrollment (Anticipated): 180

Contacts and Locations

• Study Contact: Name: Shushan Li, MD; Phone Number: 0086-135-5237-4266; Email: shushan_li@yeah.net

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100191
      • Recruiting
      • Peking University Third Hosipital
      • Contact: Pro. Zhang, PHD, MD; Phone Number: 0086-186-0103-1059; Email: zhangc1@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 80 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All the patients that visit the Peking University Third Hospital from July 2014 to July 2019 and are diognosed as Posner-Schlossman Syndrome, age-related cataract, or primary open-angle glaucoma.

Description

Inclusion Criteria:

• Volunteer to take part in this study and sign informed consent by oneself or the patient's legal representative
• Clinical diagnosis of Posner-Schlossman Syndrome, age-related cataract, or primary open-angle glaucoma
• Live in Beijing, China or being able to visit the Peking University Third Hospital every year after the beginning of the study or whenever the disease relapses

Exclusion Criteria:

• Fit any exclusion criteria of the patient's group

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
Posner-Schlossman Syndrome; Inclusion criteria： Clinical diagnosis of Posner-Schlossman Syndrome; Able to communicate with doctor and understand this study Exclusion criteria: Not be able to communicate with doctor and understand this study; One or more authorized investigators think he or she will suffer from any severe risks from the study
cataract; Inclusion criteria： Clinical diagnosis of age-related cataract; Prepare for cataract operation; Open angle and intraocular pressure is normally at anytime; No family history of glaucoma Exclusion criteria: Patients above 65 years old; With Secondary ocular hypertension; Have the history of receiving any ophthalmologic operation or anti-viral therapy; With diabetes mellitus; With autoimmune disease; Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month
primary open-angle glaucoma; Inclusion criteria： Both eyes involved; Open angle; Progressive glaucomatous optic neuropathy; Specific visual field loss of glaucoma; Intraocular pressure above the up limit of normal people Exclusion criteria: Patients above 65 years old; With Secondary ocular hypertension; Have the history of receiving any ophthalmologic operation or anti-viral therapy; With diabetes mellitus; With autoimmune disease; Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
demographic characteristics	age, sex, education level, systemic disease， mental state	up to 10 years
visual acuity	uncorrected visual acuity and best corrected visual acuity	up to 10 years
intraocular pressure	Goldmann	up to 10 years
slit-lamp examination	anterior segment	up to 10 years
fundus photograph	analysis the morphology of optic nerve head	up to 10 years
OCT	zess	up to 10 years
visual field	Humphrey visual field	up to 10 years
blood serum	8ml	up to 10 years
aqueous humor	0.2ml	up to 10 years
tissue	iris and& or trabecular meshwork tissue abandoned in the anti-glaucoma operation	in the operation

Collaborators and Investigators

• Sponsor: Peking University
• Investigators: Study Director: Chun Zhang, PHD,MD, Peking University Third Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 31, 2014
• Primary Completion (Anticipated): July 31, 2024
• Study Completion (Anticipated): July 31, 2024

Study Registration Dates

• First Submitted: July 22, 2017
• First Submitted That Met QC Criteria: July 27, 2017
• First Posted (Actual): July 28, 2017

Study Record Updates

• Last Update Posted (Actual): October 14, 2020
• Last Update Submitted That Met QC Criteria: October 11, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: cytomegalovirus; Posner Schlossman Syndrome; cytokine expression
• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome
• Other Study ID Numbers: IRB00006761-2014166

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No